• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Bioventus Inc. (Amendment)

    1/22/24 4:07:56 PM ET
    $BVS
    Medical/Dental Instruments
    Health Care
    Get the next $BVS alert in real time by email
    SC 13G/A 1 d676404dsc13ga.htm SC 13G/A SC 13G/A

     

     

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

    (Amendment No. 1)*

     

     

    BIOVENTUS INC.

    (Name of Issuer)

    Class A Common Stock, par value $0.001 per share

    (Title of Class of Securities)

    09075A108

    (CUSIP Number)

    Martin P. Sutter

    EW Healthcare Partners Acquisition Fund, L.P.

    21 Waterway Avenue, Suite 225

    The Woodlands, Texas 77380

    (281) 364-1555

    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

    December 31, 2023

    (Date of Event which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

      ☐

    Rule 13d-1(b)

     

      ☐

    Rule 13d-1(c)

     

      ☒

    Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


     1   

     NAME OF REPORTING PERSON

     S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

     

     EW Healthcare Partners Acquisition Fund, L.P.

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     (a) ☐  (b) ☒

     

     3  

     SEC USE ONLY

     

     4  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Delaware

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5   

     SOLE VOTING POWER

     

     12,096,702

       6  

     SHARED VOTING POWER

     

     -0-

       7  

     SOLE DISPOSITIVE POWER

     

     12,096,702

       8  

     SHARED DISPOSITIVE POWER

     

     -0-

     9   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     12,096,702

    10  

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

     ☐

    11  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

     19.2%

    12  

     TYPE OF REPORTING PERSON

     

     PN


     1   

     NAME OF REPORTING PERSON

     S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

     

     EW Healthcare Partners Acquisition Fund GP, L.P.

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     (a) ☐  (b) ☒

     

     3  

     SEC USE ONLY

     

     4  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Delaware

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5    

     SOLE VOTING POWER

     

     13,021,324

       6   

     SHARED VOTING POWER

     

     -0-

       7   

     SOLE DISPOSITIVE POWER

     

     13,021,324

       8   

     SHARED DISPOSITIVE POWER

     

     -0-

     9   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     13,021,324

    10  

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

     ☐

    11  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

     20.7%

    12  

     TYPE OF REPORTING PERSON

     

     PN


     1   

     NAME OF REPORTING PERSON

     S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

     

     EW Healthcare Partners Acquisition Fund UGP, LLC

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     (a) ☐  (b) ☒

     

     3  

     SEC USE ONLY

     

     4  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Delaware

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5    

     SOLE VOTING POWER

     

     13,021,324

       6   

     SHARED VOTING POWER

     

     -0-

       7   

     SOLE DISPOSITIVE POWER

     

     13,021,324

       8   

     SHARED DISPOSITIVE POWER

     

     -0-

     9   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     13,021,324

    10  

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

     ☐

    11  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

     20.7%

    12  

     TYPE OF REPORTING PERSON

     

     CO


     1   

     NAME OF REPORTING PERSON

     S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

     

     White Pine Medical LLC

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     (a) ☐  (b) ☒

     

     3  

     SEC USE ONLY

     

     4  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Delaware

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5    

     SOLE VOTING POWER

     

     924,622

       6   

     SHARED VOTING POWER

     

     -0-

       7   

     SOLE DISPOSITIVE POWER

     

     924,622

       8   

     SHARED DISPOSITIVE POWER

     

     -0-

     9   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     924,622

    10  

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

     ☐

    11  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

     1.5%

    12  

     TYPE OF REPORTING PERSON

     

     CO


     1   

     NAME OF REPORTING PERSON

     S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

     

     Martin P. Sutter

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     (a) ☐  (b) ☒

     

     3  

     SEC USE ONLY

     

     4  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     United States

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5    

     SOLE VOTING POWER

     

     -0-

       6   

     SHARED VOTING POWER

     

     13,021,324

       7   

     SOLE DISPOSITIVE POWER

     

     -0-

       8   

     SHARED DISPOSITIVE POWER

     

     13,021,324

     9   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     13,021,324

    10  

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

     ☐

    11  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

     20.7%

    12  

     TYPE OF REPORTING PERSON

     

     IN


     1   

     NAME OF REPORTING PERSON

     S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

     

     Petri Vainio

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     (a) ☐  (b) ☒

     

     3  

     SEC USE ONLY

     

     4  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     United States

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5    

     SOLE VOTING POWER

     

     -0-

       6   

     SHARED VOTING POWER

     

     13,021,324

       7   

     SOLE DISPOSITIVE POWER

     

     -0-

       8   

     SHARED DISPOSITIVE POWER

     

     13,021,324

     9   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     13,021,324

    10  

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

     ☐

    11  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

     20.7%

    12  

     TYPE OF REPORTING PERSON

     

     IN


     1   

     NAME OF REPORTING PERSON

     S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

     

     Ron Eastman

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     (a) ☐  (b) ☒

     

     3  

     SEC USE ONLY

     

     4  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     United States

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5    

     SOLE VOTING POWER

     

     -0-

       6   

     SHARED VOTING POWER

     

     13,021,324

       7   

     SOLE DISPOSITIVE POWER

     

     -0-

       8   

     SHARED DISPOSITIVE POWER

     

     13,021,324

     9   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     13,021,324

    10  

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

     ☐

    11  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

     20.7%

    12  

     TYPE OF REPORTING PERSON

     

     IN


     1   

     NAME OF REPORTING PERSON

     S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

     

     R. Scott Barry

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     (a) ☐  (b) ☒

     

     3  

     SEC USE ONLY

     

     4  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     United States

    NUMBER OF

    SHARES

     BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5    

     SOLE VOTING POWER

     

     -0-

       6   

     SHARED VOTING POWER

     

     13,021,324

       7   

     SOLE DISPOSITIVE POWER

     

     -0-

       8   

     SHARED DISPOSITIVE POWER

     

     13,021,324

     9   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     13,021,324

    10  

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

     ☐

    11  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

     20.7%

    12  

     TYPE OF REPORTING PERSON

     

     IN


    SCHEDULE 13G/A

    Item 1.

     

      (a)

    Name of Issuer:

    Bioventus Inc.

     

      (b)

    Address of Issuer’s Principal Executive Offices:

    4721 Emperor Boulevard, Suite 100, Durham, North Carolina 27703

    Item 2.

     

      (a)

    Name of Person Filing:

    This Amendment No. 1 to Schedule 13G amends the Schedule 13G filed on January 31, 2022 and is being filed jointly by EW Healthcare Partners Acquisition Fund, L.P., a Delaware limited partnership (“EWHP”), White Pine Medical LLC, a Delaware limited liability company (“WPM”), EW Healthcare Partners Acquisition Fund GP, L.P., a Delaware limited partnership, the general partner of EWHP (the “EWHP GP”), EW Healthcare Partners Acquisition Fund UGP, LLC, a Delaware limited liability company, the general partner of EWHP GP (the “General Partner”), Martin P. Sutter, an individual, Petri Vainio, an individual, Ron Eastman, an individual, and R. Scott Barry, an individual, (each a “Manager”, collectively, the “Managers”, and together with EWHP, WPM, EWHP GP and the General Partner, the “Reporting Persons”).

     

      (b)

    Address of Principal Business Office:

    The address of the principal business of each of the Reporting Persons is 21 Waterway, Suite 225, The Woodlands, Texas 77380.

     

      (c)

    Citizenship:

    (i) EWHP and EWHP GP are each Delaware limited partnerships; (ii) WPM and the General Partner are each a Delaware limited liability company; and (iii) each Manager is an individual who is a citizen of the United States.

     

      (d)

    Title and Class of Securities:

    Class A Common Stock, par value $.001 per share (“Class A Common Stock”).

     

      (e)

    CUSIP Number:

    09075A108

    Item 3. If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

    Not applicable.

    Item 4. Ownership.

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

     

    (a)

    Amount Beneficially Owned:

    For EWHP, 12,096,702 shares.

    For WPM, 924,622 shares.

    For each of EWHP GP and the General Partner, 13,021,324 shares.

    For each of the Managers: 13,021,324 shares.


    (b)

    Percent of Class:(1)

    For EWHP, 19.2 %.

    For WPM, 1.5%.

    For each of EWHP GP and the General Partner, 20.7%.

    For each of the Managers: 20.7%.

     

    (c)

    Number of shares as to which such person has:

     

      (i)

    Sole power to vote or to direct the vote:

    For EWHP, 12,096,702 shares.

    For WPM, 924,622 shares.

    For each of EWHP GP and the General Partner, 13,021,324 shares.

    For each of the Managers: 0 shares.

     

      (ii)

    Shared power to vote or to direct the vote:

    For EWHP, 0 shares.

    For WPM, 0 shares.

    For each of EWHP GP and the General Partner, 0 shares.

    For each of the Managers: 13,021,324 shares.

     

      (iii)

    Sole power to dispose or to direct the disposition of:

    For EWHP, 12,096,702 shares.

    For WPM, 924,622 shares.

    For each of EWHP GP and the General Partner, 13,021,324 shares.

    For each of the Managers: 0 shares.

     

      (iv)

    Shared power to dispose or to direct the disposition of:

    For EWHP, 0 shares.

    For WPM, 0 shares.

    For each of EWHP GP and the General Partner, 0 shares.

    For each of the Managers: 13,021,324 shares.

     

      (1)

    Based on 62,965,830 shares of Class A Common Stock outstanding on October 27, 2023, as reported in the Issuer’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2023 filed with the U.S. Securities and Exchange Commission on November 7, 2023.

    Item 5. Ownership of Five Percent or Less of a Class

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☐.

    Item 6. Ownership of More than Five Percent on Behalf of Another Person

    Not applicable.

    Item 7. Identification and Classification of the Subsidiary which Acquired the Security Being Reported on by the Parent Holding Company

    Not applicable.

    Item 8. Identification and Classification of Members of the Group

    Not applicable.


    Item 9. Notice of Dissolution of Group

    Not applicable.

    Item 10. Certification

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having the purpose or effect.


    SIGNATURES

    After reasonable inquiry and to the best of our knowledge and belief, the undersigned certify that the information set forth in this statement is true, complete and correct.

    Date: January 22, 2024

     

    EW HEALTHCARE PARTNERS       INDIVIDUALS:
    ACQUISITION FUND, L.P.      
    By: EW Healthcare Partners Acquisition Fund GP, L.P.,      

    /s/ Martin P. Sutter

       Its General Partner          Name: Martin P. Sutter
    By:    EW Healthcare Partners Acquisition Fund UGP, LLC,      
       Its General Partner      

    /s/ R. Scott Barry

                Name: R. Scott Barry
    By:   

    /s/ Martin P. Sutter

         
       Name:    Martin P. Sutter      
       Title:    Managing Director      
    WHITE PINE MEDICAL LLC      

    /s/ Ronald Eastman

                Name: Ronald Eastman
    By:    EW Healthcare Partners Acquisition Fund,      

    /s/ Petri Vainio

       L.P., its Managing Member       Name: Petri Vainio
    By:    EW Healthcare Partners Acquisition Fund      
       GP, L.P., Its General Partner      
    By:    EW Healthcare Partners Acquisition Fund      
    UGP, LLC, Its General Partner      
    By:   

    /s/ Martin P. Sutter

         
       Name:    Martin P. Sutter      
       Title:    Managing Director      
    EW HEALTHCARE PARTNERS      
    ACQUISITION FUND GP, L.P.      
    By:    EW Healthcare Partners Acquisition Fund      
    UGP, LLC, Its General Partner      
    By:   

    /s/ Martin P. Sutter

         
       Name:    Martin P. Sutter      
       Title:    Managing Director      


    EW HEALTHCARE PARTNERS
    ACQUISITION FUND UGP, LLC
    By:  

    /s/ Martin P. Sutter

      Name:   Martin P. Sutter
      Title:   Managing Director
    Get the next $BVS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BVS

    DatePrice TargetRatingAnalyst
    12/17/2024$12.00 → $13.00Underweight → Neutral
    Analyst
    12/7/2023$7.00Hold → Buy
    Canaccord Genuity
    8/9/2023$4.00 → $6.00Hold → Buy
    Craig Hallum
    11/22/2022Buy → Hold
    Craig Hallum
    11/9/2022$18.00 → $6.00Buy → Hold
    Canaccord Genuity
    11/9/2022Overweight → Underweight
    JP Morgan
    3/15/2022$30.00Buy
    Craig Hallum
    3/11/2022$20.00 → $18.00Overweight
    Morgan Stanley
    More analyst ratings

    $BVS
    Financials

    Live finance-specific insights

    See more
    • Bioventus to Report First Quarter of Fiscal Year 2025 Financial Results on May 6, 2025

      DURHAM, N.C., April 28, 2025 (GLOBE NEWSWIRE) -- Bioventus Inc. (NASDAQ:BVS) ("Bioventus" or the "Company"), a global leader in innovations for active healing, today announced that it will report financial results for the first quarter of fiscal year 2025 before the market opens on Tuesday, May 6, 2025. The Company's management will host a conference call at 8:30 a.m. Eastern Time that same day to discuss the results and provide a business update. To participate in the conference call, dial 1-833-636-0497 and refer to the Bioventus Inc. Conference Call. A live webcast of the call and accompanying materials will also be provided on the "Investor Relations" section of the Company's website

      4/28/25 8:00:00 AM ET
      $BVS
      Medical/Dental Instruments
      Health Care
    • Bioventus to Report Fourth Quarter of Fiscal Year 2024 Financial Results on March 11, 2025

      DURHAM, N.C., Feb. 28, 2025 (GLOBE NEWSWIRE) -- Bioventus Inc. (NASDAQ:BVS) ("Bioventus" or the "Company"), a global leader in innovations for active healing, today announced that it will report financial results for the fourth quarter of fiscal year 2024 before the market opens on Tuesday, March 11, 2025. The Company's management will host a conference call at 8:30 a.m. Eastern Time that same day to discuss the results and provide a business update. To participate in the conference call, dial 1-833-636-0497 and refer to the Bioventus Inc. Conference Call. A live webcast of the call and accompanying materials will also be provided on the "Investor Relations" section of the Company's webs

      2/28/25 7:30:00 AM ET
      $BVS
      Medical/Dental Instruments
      Health Care
    • Bioventus to Report Third Quarter of Fiscal Year 2024 Financial Results on November 5, 2024

      DURHAM, N.C., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Bioventus Inc. (NASDAQ:BVS) ("Bioventus" or the "Company"), a global leader in innovations for active healing, today announced that it will report financial results for the third quarter of fiscal year 2024 before the market opens on Tuesday, November 5, 2024. The Company's management will host a conference call at 8:30 a.m. Eastern Time that same day to discuss the results and provide a business update. To participate in the conference call, dial 1-833-636-0497 and refer to the Bioventus Inc. Conference Call. A live webcast of the call and accompanying materials will also be provided on the "Investor Relations" section of the Company's web

      10/29/24 7:30:00 AM ET
      $BVS
      Medical/Dental Instruments
      Health Care

    $BVS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SVP & CFO Singleton Mark Leonard sold $29,334 worth of shares (3,875 units at $7.57), decreasing direct ownership by 3% to 141,088 units (SEC Form 4)

      4 - Bioventus Inc. (0001665988) (Issuer)

      4/15/25 5:50:38 PM ET
      $BVS
      Medical/Dental Instruments
      Health Care
    • SVP & General Counsel D'Adamio Anthony sold $22,392 worth of shares (2,958 units at $7.57), decreasing direct ownership by 2% to 131,416 units (SEC Form 4)

      4 - Bioventus Inc. (0001665988) (Issuer)

      4/15/25 5:50:10 PM ET
      $BVS
      Medical/Dental Instruments
      Health Care
    • SVP & Chief Compliance Officer Church Katrina J sold $9,712 worth of shares (1,283 units at $7.57), decreasing direct ownership by 2% to 55,557 units (SEC Form 4)

      4 - Bioventus Inc. (0001665988) (Issuer)

      4/15/25 5:49:31 PM ET
      $BVS
      Medical/Dental Instruments
      Health Care

    $BVS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Bioventus Inc.

      SC 13G/A - Bioventus Inc. (0001665988) (Subject)

      11/8/24 9:13:26 PM ET
      $BVS
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Bioventus Inc.

      SC 13G/A - Bioventus Inc. (0001665988) (Subject)

      7/15/24 5:15:58 PM ET
      $BVS
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by Bioventus Inc. (Amendment)

      SC 13G/A - Bioventus Inc. (0001665988) (Subject)

      2/14/24 4:51:41 PM ET
      $BVS
      Medical/Dental Instruments
      Health Care

    $BVS
    SEC Filings

    See more
    • SEC Form SD filed by Bioventus Inc.

      SD - Bioventus Inc. (0001665988) (Filer)

      6/2/25 5:10:41 PM ET
      $BVS
      Medical/Dental Instruments
      Health Care
    • SEC Form 10-Q filed by Bioventus Inc.

      10-Q - Bioventus Inc. (0001665988) (Filer)

      5/6/25 7:38:47 AM ET
      $BVS
      Medical/Dental Instruments
      Health Care
    • Bioventus Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Bioventus Inc. (0001665988) (Filer)

      5/6/25 7:36:54 AM ET
      $BVS
      Medical/Dental Instruments
      Health Care

    $BVS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Bioventus upgraded by Analyst with a new price target

      Analyst upgraded Bioventus from Underweight to Neutral and set a new price target of $13.00 from $12.00 previously

      12/17/24 7:32:13 AM ET
      $BVS
      Medical/Dental Instruments
      Health Care
    • Bioventus upgraded by Canaccord Genuity with a new price target

      Canaccord Genuity upgraded Bioventus from Hold to Buy and set a new price target of $7.00

      12/7/23 6:14:32 AM ET
      $BVS
      Medical/Dental Instruments
      Health Care
    • Bioventus upgraded by Craig Hallum with a new price target

      Craig Hallum upgraded Bioventus from Hold to Buy and set a new price target of $6.00 from $4.00 previously

      8/9/23 7:43:55 AM ET
      $BVS
      Medical/Dental Instruments
      Health Care

    $BVS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Bartholdson John A. bought $901,702 worth of shares (105,500 units at $8.55) (SEC Form 4)

      4 - Bioventus Inc. (0001665988) (Issuer)

      8/20/24 6:16:00 PM ET
      $BVS
      Medical/Dental Instruments
      Health Care

    $BVS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Bioventus to Report First Quarter of Fiscal Year 2025 Financial Results on May 6, 2025

      DURHAM, N.C., April 28, 2025 (GLOBE NEWSWIRE) -- Bioventus Inc. (NASDAQ:BVS) ("Bioventus" or the "Company"), a global leader in innovations for active healing, today announced that it will report financial results for the first quarter of fiscal year 2025 before the market opens on Tuesday, May 6, 2025. The Company's management will host a conference call at 8:30 a.m. Eastern Time that same day to discuss the results and provide a business update. To participate in the conference call, dial 1-833-636-0497 and refer to the Bioventus Inc. Conference Call. A live webcast of the call and accompanying materials will also be provided on the "Investor Relations" section of the Company's website

      4/28/25 8:00:00 AM ET
      $BVS
      Medical/Dental Instruments
      Health Care
    • Bioventus to Report Fourth Quarter of Fiscal Year 2024 Financial Results on March 11, 2025

      DURHAM, N.C., Feb. 28, 2025 (GLOBE NEWSWIRE) -- Bioventus Inc. (NASDAQ:BVS) ("Bioventus" or the "Company"), a global leader in innovations for active healing, today announced that it will report financial results for the fourth quarter of fiscal year 2024 before the market opens on Tuesday, March 11, 2025. The Company's management will host a conference call at 8:30 a.m. Eastern Time that same day to discuss the results and provide a business update. To participate in the conference call, dial 1-833-636-0497 and refer to the Bioventus Inc. Conference Call. A live webcast of the call and accompanying materials will also be provided on the "Investor Relations" section of the Company's webs

      2/28/25 7:30:00 AM ET
      $BVS
      Medical/Dental Instruments
      Health Care
    • Bioventus to Present at the 43rd Annual J.P. Morgan Healthcare Conference

      DURHAM, N.C., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Bioventus Inc. (NASDAQ:BVS), a global leader in innovations for active healing, today announced that Rob Claypoole, chief executive officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025, at 10:30 a.m. PT (1:30 p.m. ET). The live webcast of the presentation, including Q&A, may be accessed on the Investors section of the Bioventus website and will be available until February 15, 2025. About BioventusBioventus delivers clinically proven, cost-effective products that help people heal quickly and safely. Its mission is to make a difference by helping patients resume and enjoy active lives.

      1/7/25 8:00:00 AM ET
      $BVS
      Medical/Dental Instruments
      Health Care

    $BVS
    Leadership Updates

    Live Leadership Updates

    See more
    • Apyx Medical Corporation Announces Board Leadership Transition

      Andrew Makrides Retiring Following More Than 40 Years of Service as Chairman of the Board of Directors; Stavros Vizirgianakis Appointed to Succeed Mr. Makrides as Chairman Apyx Medical Corporation (NASDAQ:APYX) ("Apyx Medical"; the "Company"), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today announced the retirement of Andrew Makrides as Chairman of the Board, after serving the Company in this position since 1982. The Board of Directors has appointed Stavros Vizirgianakis Chairman of the Board, effective as of May 7, 2024. "On behalf of the entire organization, I would like to express our gratitude to Andrew for his lead

      5/9/24 7:00:00 AM ET
      $APYX
      $BVS
      $XTNT
      Medical/Dental Instruments
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Bioventus Appoints Mark Singleton as Chief Financial Officer

      DURHAM, N.C., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Bioventus Inc. (NASDAQ:BVS) ("Bioventus" or the "Company"), a global leader in innovations for active healing, today announced that it has appointed Mark Singleton as the Company's Senior Vice President, Chief Financial Officer and Principal Accounting Officer, effective March 21, 2022. Mr. Singleton brings to Bioventus more than two decades of experience in operational finance and mergers & acquisitions at large and multi-national organizations. Most recently, he served as Vice President of Finance, Americas for Teleflex Incorporated, where he had financial responsibility for the $1.7 billion Americas business. Previous to this role, Mr. Si

      2/28/22 7:00:00 AM ET
      $BVS
      Medical/Dental Instruments
      Health Care
    • Bioventus Appoints Michelle McMurry-Heath to Board of Directors

      DURHAM, N.C., Dec. 21, 2021 (GLOBE NEWSWIRE) -- Bioventus Inc. (NASDAQ:BVS) ("Bioventus" or the "Company"), a global leader in innovations for active healing, has announced the appointment of Michelle McMurry-Heath, MD, PhD, to the Company's Board of Directors, effective January 1, 2022. Over the past 20 years, as both a physician and scientist, McMurry-Heath has served in dynamic policy, regulatory, commercial health care and advocacy roles. She will join the Board as an independent director. "We are thrilled Michelle will be joining the Bioventus Board of Directors," said Ken Reali, CEO. "Bioventus will leverage her background as a global medical innovation strategist as well as her ex

      12/21/21 9:25:00 AM ET
      $BVS
      Medical/Dental Instruments
      Health Care